New pill takes on aggressive brain tumors in early trial
NCT ID NCT07464925
First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This early-stage trial tests an oral drug called GLIX1 in 30 adults with recurrent or progressive high-grade glioma, a fast-growing brain cancer. The study aims to find the safest dose and check for any signs of tumor control. Participants take the drug daily until their disease gets worse or side effects become unacceptable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern Medicine
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLIX1 (oral capsule)
What this could lead to
If it works, this could point toward a new treatment option for people with aggressive brain tumors that have come back after standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 30 people. The main goal is safety and dosing, not yet proof of effectiveness. Side effects are unknown and the drug may not shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.